インターフェロンの世界市場2019-2023

◆英語タイトル:Global Interferons Market 2019-2023
◆商品コード:IRTNTR30806
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年2月23日
◆ページ数:119
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥312,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、インターフェロンの世界市場について調査・分析し、市場概要、市場環境、インターフェロン市場規模、タイプ別(インターフェロンベータ、インターフェロンアルファ、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・インターフェロンの世界市場概要
・インターフェロンの世界市場環境
・インターフェロンの世界市場動向
・インターフェロンの世界市場規模
・インターフェロンの世界市場:業界構造分析
・インターフェロンの世界市場:タイプ別(インターフェロンベータ、インターフェロンアルファ、その他)
・インターフェロンの世界市場:地域別市場規模・分析
・インターフェロンの北米市場規模・予測
・インターフェロンのヨーロッパ・中東・アフリカ市場規模・予測
・インターフェロンのアジア太平洋市場規模・予測
・インターフェロンの主要国分析
・インターフェロンの世界市場:意思決定フレームワーク
・インターフェロンの世界市場:成長要因、課題
・インターフェロンの世界市場:競争環境
・インターフェロンの世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market
Interferons belong to the family of cytokines, a group of small proteins essential in cell signaling. They are synthesized and delivered by host cells in response to a pathogen’s harmful activities. They are generally used for treating immune system-related diseases such as cancer, hepatitis, ADS, multiple sclerosis, genital and perianal warts, and granulomatous disease. Since these therapeutics directly work on the target, they demonstrate higher efficacy than conventional treatments. Therefore, the versatility of this therapeutic class makes it one of the preferred treatment choices by medical practitioners, as well as patients, thereby driving market growth. Interferons have high target affinity, which is expected to increase their demand, thereby driving market growth. Technavio’s analysts have predicted that the interferons market will register a CAGR of almost 2% by 2023.
Market Overview
Advent of novel drug delivery and combination therapies
Considering their biological nature, interferons are mostly administered through the intravenous RoA due to which they are associated with side effects such as redness, irritation, and swelling at the injection site. Thus, they can significantly improve patient compliance and help in better management of hepatitis B.
High cost associated with treatment
Treatment cost is one of the major challenges for patients suffering from diseases such as multiple sclerosis and cancer. High treatment cost restricts the adoption of drugs. which reduces patient adherence and poses a challenge to market growth.
For the detailed list of factors that will drive and challenge the growth of the interferons market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be mildly concentrated and with the presence of few companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Interferon beta – Market size and forecast 2018-2023
• Interferon alfa – Market size and forecast 2018-2023
• Other interferons – Market size and forecast 2018-2023
• Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer AG
• Biogen
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Merck Sharp & Dohme Corp.
PART 13: APPENDIX
• Research methodology
• List of abbreviations


Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Type – Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Interferon beta – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Interferon beta – Year-over-year growth 2019-2023 (%)
Exhibit 22: Interferon alfa – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Interferon alfa – Year-over-year growth 2019-2023 (%)
Exhibit 24: Other interferons – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Other interferons – Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Prevalence of cancer types in the US
Exhibit 32: North America – Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in North America
Exhibit 34: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Europe
Exhibit 37: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Approved biosimilars
Exhibit 39: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Decision framework
Exhibit 47: Treatment costs of interferon therapeutics used for treatment of various diseases
Exhibit 48: Side effects of interferon therapeutics
Exhibit 49: Recently approved substitutes to interferons
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Some interferon biosimilars in market
Exhibit 52: Vendor landscape
Exhibit 53: Landscape disruption
Exhibit 54: Vendors covered
Exhibit 55: Vendor classification
Exhibit 56: Market positioning of vendors
Exhibit 57: Bayer AG – Vendor overview
Exhibit 58: Bayer AG – Product segments
Exhibit 59: Bayer AG – Organizational developments
Exhibit 60: Bayer AG – Geographic focus
Exhibit 61: Bayer AG – Segment focus
Exhibit 62: Bayer AG – Key offerings
Exhibit 63: Bayer AG – Key customers
Exhibit 64: Biogen – Vendor overview
Exhibit 65: Biogen – Product segments
Exhibit 66: Biogen – Organizational developments
Exhibit 67: Biogen – Geographic focus
Exhibit 68: Biogen – Key offerings
Exhibit 69: Biogen – Key customers
Exhibit 70: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 71: F. Hoffmann-La Roche Ltd. – Business segments
Exhibit 72: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 73: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 74: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 75: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 76: F. Hoffmann-La Roche Ltd. – Key customers
Exhibit 77: Merck KGaA – Vendor overview
Exhibit 78: Merck KGaA – Business segments
Exhibit 79: Merck KGaA – Organizational developments
Exhibit 80: Merck KGaA – Geographic focus
Exhibit 81: Merck KGaA – Segment focus
Exhibit 82: Merck KGaA – Key offerings
Exhibit 83: Merck KGaA – Key customers
Exhibit 84: Merck Sharp & Dohme Corp. – Vendor overview
Exhibit 85: Merck Sharp & Dohme Corp. – Business segments
Exhibit 86: Merck Sharp & Dohme Corp. – Organizational developments
Exhibit 87: Merck Sharp & Dohme Corp. – Geographic focus
Exhibit 88: Merck Sharp & Dohme Corp. – Segment focus
Exhibit 89: Merck Sharp & Dohme Corp. – Key offerings
Exhibit 90: Merck Sharp & Dohme Corp. – Key customers
Exhibit 91: Validation techniques employed for market sizing
Exhibit 92: List of abbreviations



【掲載企業】

Bayer AG、Biogen、F. Hoffmann-La Roche Ltd.、Merck KGaA、and Merck Sharp & Dohme Corp

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[インターフェロンの世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆